Bayer Execs Silent On Plans To Divest Material Sciences
This article was originally published in The Pink Sheet Daily
Executive Summary
The diversified German big pharma highlighted the sales growth of its five recently launched drugs in the first quarter, but declined to fuel M&A speculation surrounding its non-life sciences division.
You may also be interested in...
Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field
FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.